Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis

Author: C. Beyer, N. Reich, S. Schindler, et al
Date Published: January-2012
Source: Annals of the Rheumatic Diseases

Fibrosis and vascular disease are cardinal features of systemic sclerosis (SSc). Stimulators of soluble guanylate cyclase (sGC) are vasoactive drugs that are currently being evaluated in phase III clinical trials for pulmonary arterial hypertension.


AddThis Social Bookmark Button